ABT737 reverses cisplatin resistance by regulating ER-mitochondria Ca2+ signal transduction in human ovarian cancer cells

  • Authors:
    • Qi Xie
    • Jing Su
    • Bingxuan Jiao
    • Luyan Shen
    • Liwei Ma
    • Xianzhi Qu
    • Chunyan Yu
    • Xianrui Jiang
    • Ye Xu
    • Liankun Sun
  • View Affiliations

  • Published online on: October 13, 2016     https://doi.org/10.3892/ijo.2016.3733
  • Pages: 2507-2519
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Bcl-2, which belongs to the Bcl-2 family, is frequently overexpressed in various types of cancer cells and contributes to drug resistance. However, the function of Bcl-2 in cisplatin resistance in human ovarian cancer cells is not fully understood. In this study, we found that the pharmacological inhibitor ABT737 or genetic knockdown of Bcl-2 increased cisplatin cytotoxicity in cisplatin-resistant ovarian cancer cells. Additionally, treatment with ABT737 or Bcl-2 siRNA increased cisplatin-induced free Ca2+ levels in the cytosol and mitochondria, which increased endoplasmic reticulum (ER)-associated and mitochondria-mediated apoptosis. In addition, ABT737 or Bcl-2 siRNA increased the ER-mitochondria contact sites induced by cisplatin in cisplatin-resistant SKOV3/DDP ovarian cancer cells. Consistently with the in vitro results, ABT737 potently synergized with cisplatin in inhibiting the growth of human ovarian cancer xenografts in nude mice. Collectively, these results indicate that pharmacological inhibitors or genetic knockdown of Bcl-2 may be a potential strategy for improving cisplatin treatment of ovarian cancer.
View Figures
View References

Related Articles

Journal Cover

December-2016
Volume 49 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Xie Q, Su J, Jiao B, Shen L, Ma L, Qu X, Yu C, Jiang X, Xu Y, Sun L, Sun L, et al: ABT737 reverses cisplatin resistance by regulating ER-mitochondria Ca2+ signal transduction in human ovarian cancer cells. Int J Oncol 49: 2507-2519, 2016.
APA
Xie, Q., Su, J., Jiao, B., Shen, L., Ma, L., Qu, X. ... Sun, L. (2016). ABT737 reverses cisplatin resistance by regulating ER-mitochondria Ca2+ signal transduction in human ovarian cancer cells. International Journal of Oncology, 49, 2507-2519. https://doi.org/10.3892/ijo.2016.3733
MLA
Xie, Q., Su, J., Jiao, B., Shen, L., Ma, L., Qu, X., Yu, C., Jiang, X., Xu, Y., Sun, L."ABT737 reverses cisplatin resistance by regulating ER-mitochondria Ca2+ signal transduction in human ovarian cancer cells". International Journal of Oncology 49.6 (2016): 2507-2519.
Chicago
Xie, Q., Su, J., Jiao, B., Shen, L., Ma, L., Qu, X., Yu, C., Jiang, X., Xu, Y., Sun, L."ABT737 reverses cisplatin resistance by regulating ER-mitochondria Ca2+ signal transduction in human ovarian cancer cells". International Journal of Oncology 49, no. 6 (2016): 2507-2519. https://doi.org/10.3892/ijo.2016.3733